Top MarketRank™ StocksTop MarketRank™NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $381.47 +0.97 (+0.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$373.99▼$385.7050-Day Range$357.30▼$457.2952-Week Range$227.21▼$459.77Volume473,845 shsAverage Volume245,488 shsMarket Capitalization$11.83 billionP/E Ratio38.89Dividend YieldN/APrice Target$424.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside11.2% Upside$424.14 Price TargetShort InterestHealthy3.26% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.37Based on 51 Articles This WeekInsider TradingSelling Shares$11.82 M Sold Last QuarterProj. Earnings Growth13.29%From $11.59 to $13.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.97 out of 5 starsMedical Sector5th out of 936 stocksCommercial Physical Research Industry1st out of 12 stocks 3.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.26% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently decreased by 15.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 3.0 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 51 news articles for Medpace this week, compared to 8 articles on an average week.Search Interest11 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows10 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,816,852.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 13.29% in the coming year, from $11.59 to $13.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 38.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 38.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 15.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesJuly 26 at 7:10 AM | americanbankingnews.comWilliam Blair Reiterates Outperform Rating for Medpace (NASDAQ:MEDP)July 25 at 10:55 AM | finance.yahoo.comMedpace Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 10:50 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Given New $336.00 Price Target at Deutsche Bank AktiengesellschaftJuly 25 at 9:38 AM | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) to Post Q3 2024 Earnings of $2.74 Per Share, William Blair ForecastsJuly 25 at 7:10 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Price Target Lowered to $432.00 at GuggenheimJuly 25 at 6:08 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Price Target Lowered to $430.00 at Robert W. BairdJuly 25 at 1:18 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Sees Large Volume Increase After Earnings BeatJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 24 at 2:36 PM | yahoo.comEuropean Stocks Give Up Gains as Earnings Come Thick and FastJuly 24 at 2:36 PM | finance.yahoo.comMedpace Holdings Second Quarter 2024 Earnings: EPS Beats ExpectationsJuly 24 at 2:36 PM | markets.businessinsider.comExpert Ratings For Medpace HldgsJuly 24 at 11:18 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Updates FY24 Earnings GuidanceJuly 24 at 10:26 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Given New $434.00 Price Target at TD CowenJuly 23 at 8:15 PM | benzinga.comMedpace Hldgs (NASDAQ:MEDP) Stock Quotes, Forecast and News SummaryJuly 23 at 11:50 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Issues FY 2024 Earnings GuidanceJuly 23 at 10:07 AM | seekingalpha.comMedpace Holdings, Inc. 2024 Q2 - Results - Earnings Call PresentationJuly 23 at 8:18 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Announces Earnings ResultsSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2024Today7/26/2024Next Earnings (Estimated)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$424.14 High Stock Price Target$452.00 Low Stock Price Target$336.00 Potential Upside/Downside+10.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio39.26 Forward P/E Ratio33.23 P/E Growth1.84Net Income$282.81 million Net Margins16.74% Pretax Margin19.57% Return on Equity55.14% Return on Assets19.82% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.78 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.33 Cash Flow$10.16 per share Price / Cash Flow37.90 Book Value$24.63 per share Price / Book15.64Miscellaneous Outstanding Shares31,000,000Free Float24,693,000Market Cap$11.94 billion OptionableOptionable Beta1.36 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.65MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $945.08kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $690.48kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1.12MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $914.64kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELSyneos HealthNASDAQ:SYNHPrecigenNASDAQ:PGENIQVIANYSE:IQVView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 1,128 shares on 7/26/2024Ownership: 0.730%Legato Capital Management LLCSold 1,922 shares on 7/26/2024Ownership: 0.015%Catalyst Capital Advisors LLCBought 2,150 shares on 7/26/2024Ownership: 0.007%Smith Shellnut Wilson LLC ADVBought 963 shares on 7/26/2024Ownership: 0.003%RiverPark Advisors LLCBought 53 shares on 7/26/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $306.53 at the start of the year. Since then, MEDP stock has increased by 24.4% and is now trading at $381.47. View the best growth stocks for 2024 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings data on Monday, July, 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.54 by $0.21. The business's quarterly revenue was up 14.6% compared to the same quarter last year. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Top institutional shareholders of Medpace include Riverbridge Partners LLC (1.73%), Westwind Capital (1.23%), Bank of New York Mellon Corp (0.73%) and Boston Trust Walden Corp (0.51%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD) and Bilibili (BILI). This page (NASDAQ:MEDP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
